[A16-22] Afatinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2016
Project no.:
A16-22
Commission:
Commission awarded on 27.04.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-17 | Afatinib - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A13-41 | Afatinib - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-10-20 A G-BA decision was published.